Management of Severe Hyperglycemia

Introduction to Insulin Therapy

The American Diabetes Association recommends initiating insulin therapy when A1c is ≥10.0%, as insulin is likely to be more effective than most other agents as the next therapeutic option 1, 4
The American Diabetes Association suggests beginning with a basal insulin (insulin glargine, detemir, or NPH) in combination with current non-insulin agents, with a starting dose of 10 IU per day, then titrated weekly to a pre-breakfast self-measured plasma glucose target of 4.0-5.5 mmol/L (72-99 mg/dL) 2, 5

The American Diabetes Association recommends considering discontinuing sulfonylureas (glipizide) when initiating insulin to reduce the risk of hypoglycemia, and maintaining GLP-1 receptor agonists like semaglutide as they can be effectively combined with insulin and may help limit weight gain 2, 3, 5
The American Diabetes Association suggests continuing metformin unless contraindicated, and continuing thiazolidinediones like pioglitazone unless there are concerns about fluid retention or heart failure 1, 3, 6

Guidelines clearly state that when A1c is ≥10.0%, insulin therapy should be strongly considered, especially in patients who have already failed multiple non-insulin medications, including a GLP-1 receptor agonist at maximum dose 1, 3, 7
Proper patient education regarding glucose monitoring techniques, insulin injection technique, insulin storage, recognition and treatment of hypoglycemia, and "sick day" rules is crucial for successful insulin therapy 2, 5

The American Diabetes Association recommends monitoring fasting blood glucose daily and adjusting basal insulin dose accordingly, and considering adding prandial (mealtime) insulin or using rapid insulin analogs if fasting glucose targets are achieved but A1c remains elevated after 3 months 2, 5
Regular follow-up, ideally within 1-2 weeks, is necessary to assess response and adjust insulin dose as needed, with consideration of referral to a certified diabetes educator if available 2, 5